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Purpose: Prostate stereotactic body radiotherapy (SBRT) may substantially recapitulate the
dose distribution of high-dose-rate (HDR) brachytherapy, representing an externally deliv-
ered “Virtual HDR” treatment method. Herein, we present 5-year outcomes from a cohort
of consecutively treated virtual HDR SBRT prostate cancer patients.
Methods: Seventy-nine patients were treated from 2006 to 2009, 40 low-risk, and 39
intermediate-risk, under IRB-approved clinical trial, to 38 Gy in four fractions. The planning
target volume (PTV) included prostate plus a 2-mm volume expansion in all directions,
with selective use of a 5-mm prostate-to-PTV expansion and proximal seminal vesicle cov-
erage in intermediate-risk patients, to better cover potential extraprostatic disease; rectal
PTV margin reduced to zero in all cases. The prescription dose covered >95% of the PTV
(V100 ≥95%), with a minimum 150% PTV dose escalation to create “HDR-like” PTV dose
distribution.
Results: Median pre-SBRT PSA level of 5.6 ng/mL decreased to 0.05 ng/mL 5 years out and
0.02 ng/mL 6 years out. At least one PSA bounce was seen in 55 patients (70%) but only
3 of them subsequently relapsed, biochemical-relapse-free survival was 100 and 92% for
low-risk and intermediate-risk patients, respectively, by ASTRO definition (98 and 92% by
Phoenix definition). Local relapse did not occur, distant metastasis-free survival was 100
and 95% by risk-group, and disease-specific survival was 100%. Acute and late grade 2 GU
toxicity incidence was 10 and 9%, respectively; with 6% late grade 3 GU toxicity. Acute
urinary retention did not occur. Acute and late grade 2 GI toxicity was 0 and 1%, respec-
tively, with no grade 3 or higher toxicity. Of patient’s potent pre-SBRT, 65% remained so
at 5 years.
Conclusion: Virtual HDR prostate SBRT creates a very low PSA nadir, a high rate of 5-year
disease-free survival and an acceptable toxicity incidence, with results closely resembling
those reported post-HDR brachytherapy.
Keywords: CyberKnife, prostate cancer, dosimetry, HDR, brachytherapy, image guided, stereotactic body
radiotherapy
INTRODUCTION
Stereotactic body radiotherapy (SBRT) is a potentially effective
treatment method for clinically localized prostate cancer, radiobio-
logically well matched to prostate cancer due to its purported high
sensitivity to fraction size, with encouraging short to intermediate-
term SBRT results reported from a number of authors and insti-
tutions (1–7). Due to the still relative newness of the SBRT
approach additional confirmatory data are desirable. If SBRT is
ultimately demonstrated to have comparable efficacy and safety
Abbreviations: CK, CyberKnife; CT, computed tomography; HDR, high-dose rate;
IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; IPSS,
international prostate symptom score; MRI, magnetic resonance imaging; PSA,
prostate-specific antigen; PTV, planning target volume; SBRT, stereotactic body
radiotherapy; US, ultrasound.
relative to other radiotherapy methods for prostate cancer, then
several practical advantages could make a compelling case for its
much more widespread adoption, including a very compressed
treatment schedule versus conventionally fractionated radiother-
apy, lower cost of delivery due to the much smaller number of
treatments, and less invasiveness versus brachytherapy (8, 9).
Prior to the advent of SBRT, high-dose-rate (HDR) brachyther-
apy also demonstrated high efficacy and reasonable safety against
localized prostate cancer (10–14). In addition to delivering favor-
able prostate cancer radiobiology due to its inherent large dose per
fraction dosimetry (comparable to SBRT), HDR brachytherapy
allows highly flexible radiation dose sculpting, with very confor-
mal tumor volume coverage and increased dose in the peripheral
zone of the prostate, so that the highest radiation dose matches
the cancer cell distribution in this region (13, 15). The primary
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drawback of HDR brachytherapy is that it is an invasive procedure,
requiring hospital admission, anesthesia, nursing support, and
narcotic analgesia to place and manage the indwelling transper-
ineal HDR catheters and deal with their attendant pain and risk of
infection or thromboembolism.
CyberKnife® (CK; Accuray Incorporated, Sunnyvale, CA, USA)
SBRT is an image-guided device capable of delivering a quantita-
tive radiation distribution to a precisely defined three-dimensional
target volume, creating very sharp surrounding dose gradients,
with sub-millimeter delivery accuracy contingent upon suffi-
cient frequent intrafraction image-guidance frequency (16). In
2008, we described a dosimetry approach whereby SBRT could
be designed to substantially recapitulate the intraprostatic and
peri-prostatic isodose morphology of HDR brachytherapy, using
CyberKnife® device as the delivery system (16, 17). The obvious
advantage of such an approach is the maintenance of HDR-like
radiobiology, conformality and intraprostatic dosimetry control,
while losing its invasive aspect. Although the main point of that
initial manuscript was to demonstrate substantial equivalence
in dose distribution between HDR prostate brachytherapy and
“Virtual HDR” CyberKnife SBRT, the larger primary study end-
points were to evaluate the efficacy and toxicity of this specific
treatment regimen. Sufficient time and patient accrual has now
occurred, such that we now report disease-free survival (DFS)
and toxicity for a larger number of consecutively treated patients
at a single institution, at risk for a minimum of 5-years of
post-treatment.
MATERIALS AND METHODS
Seventy-nine consecutive prostate cancer patients were treated
with CK SBRT from July 2006 through July 2009, under one of
two IRB-approved phase II prostate SBRT prostate monotherapy
protocols, open to low-risk patients (DRE stage T1 – T2b, Glea-
son Score ≤6, prostate-specific antigen (PSA) level ≤10 ng/ml),
and intermediate-risk patients (Gleason Score 7 or PSA level
10.1–20 ng/ml if other favorable characteristics still present) (18,
19). Our series included 40 low-risk and 39 intermediate-risk
patients with a median presenting PSA level of 5.3 ng/ml (range
1.0–19.1 ng/ml). Fifty-one patients presented with Gleason score
≤6 disease, while the remaining 28 had Gleason score 7 disease
(3+ 4− 24 pts, 4+ 3= 4 pts). Presenting patient characteristics
are described in Table 1. All patients received 38 Gy in four frac-
tions, a schedule that has been shown to be efficacious with HDR
brachytherapy (20). Standard Kaplan Meier plots were used to
describe biochemical-relapse-free survival outcomes by relapse
definition (ASTRO, Phoenix).
TREATMENT PLANNING
The planning target volume (PTV) for all cases included the
prostate as defined by our prostate MRI imaging protocol, three-
dimensionally co-registered with prostate CT imaging, matching
fiducial to fiducial, and a 2-mm volume expansion in all direc-
tions, except posteriorly where the prostate abutted the rectum,
where the margin expansion was reduced to zero based on reports
that prostate cancer does not invade posteriorly in the mid-
line beyond Denonvilliers’ fascia (21). Intermediate-risk patients
had a 5-mm dorsolateral prostate-to-PTV expansion (limited to
Table 1 | Patient characteristics.
Median age at tx (years) 68
Range 53–80
Risk group No. of patients
Low 40
Intermediate 39
Gleason No. of patients
5 1
6 50
7 28
Presenting PSA No. of patients
<10 ng/ml 68
≥10 ng/ml 11
T-stage No. of patients
1=T1b 0
2=T1c 48
3=T2a 23
4=T2b 8
Median prostate volume 39.8
Range 11.1–145.7
Presenting AUA score
Median 6
Range 0–29
Presenting SHIM score
Median 17
Range 1–25
the side of the prostate harboring the intermediate-risk lesion)
and ≥1 cm of contiguous seminal vesicle inclusion in the PTV
to more effectively cover their increased risk and potential dis-
tance of extracapsular extension near the neurovascular bundle
(NVB) (22). Typically, the 2-mm margin expansion used in favor-
able prognosis patients split the NVB as defined on T1-weighted,
gadolinium-enhanced MRI, while the 5-mm expansion used for
intermediate-prognosis patients fully encompassed it (Figure 1).
The urethra was identified by insertion of a Foley catheter, which
also provided another reference structure to use in MRI-to-CT
image co-registration.
Our CK SBRT treatment plans had a specific set of objectives
and constraints, including a requirement of a minimum PTV pre-
scription dose coverage of 95% (V100 ≥95%), a maximum PTV
dose of 200% of the prescription dose (76 Gy), with greater than
200% classified as a minor protocol deviation only. Also required
were a maximum rectal wall dose of 100% of the prescription
dose (38 Gy), a maximum rectal mucosa dose of 75% of the pre-
scription dose (28.5 Gy), a maximum urethra dose of 120% of
the prescription dose (45.6 Gy), and a maximum bladder dose of
120% of the prescription dose (45.6 Gy). The rectal mucosa was
defined as a solid structure formed by a 3-mm contraction of
the rectal wall. The normal tissue dose limitation objectives were
designed to resemble those commonly prescribed in the applica-
tion of HDR brachytherapy (23). Typical Virtual HDR CyberKnife
SBRT prostate treatment plans are demonstrated in Figure 2.
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FIGURE 1 |Typical PTV margins used in this protocol for low-risk (left
panel) and intermediate-risk (right panel) cases. The protocol calls for
Prostate+2 mm CTV to PTV expansion margins (low-risk disease) and
prostate+5 mm unilaterally or bilaterally if Gleason 7 disease or PSA
>10 ng/mL is present (intermediate-risk disease). Note “shaving” of the
GTV to PTV margin to zero against the rectum in the midline for both
risk-groups. Also note that a 2-mm PTV expansion tends to “split” the NVB
(delineated by white ovoid contour) while a 5-mm PTV expansion tends to
fully encompass it.
FIGURE 2 |This is an example of an intermediate-risk case with L-sided
Gleason score 7 disease present. Note the asymmetric GTV to PTV
expansion margins (L Panel) (2 mm around the R lobe versus 5 mm around
the L lobe) to more widely encompass the possibility of significant
extracapsular extension on the side with the higher Gleason score. This
creates wider prescription (yellow line) isodose coverage on the higher-risk
side, and also tends to create larger volumes of dose escalation within the
prostate on the more heavily involved side (center panel). Finally, note full
prescription isodose coverage (yellow line) encompassing at least 1 cm of
adjacent seminal vesicle on the sagittal image, required for intermediate-risk
cases only (SV/prostate junction denoted by the oblique black line)(R panel).
RESULTS
CLINICAL OUTCOMES
Of the 79 treated patients, all of whom were at risk for greater
than 5 years, 6 were censored due to relapse or death from other
causes, 20 were lost to follow-up while being disease-free between
6 and 54 months post-treatment (median – 42 months), and the
remaining 53 disease-free patients were followed at least 5 years.
PSA response
The median baseline pre-treatment PSA level of 5.6 ng/mL
decreased each year post-treatment, reaching a median value of
0.05 ng/mL at 5 years and thereafter decreasing further, to reach
a nadir value of 0.02 ng/mL at 6 years post-treatment. The PSA-
response to treatment at annual intervals is illustrated in Figure 3.
Although the median PSA level for the entire treated population
decreased with each annual follow-up interval out to 6 years, the
phenomenon known as “benign PSA bounce” was also common
FIGURE 3 | Entire study population: median PSA at presentation and
at annual follow-up intervals post-SBRT.
and, in fact, only 24/79 (30%) patients had a continuous PSA
decrease throughout their entire follow-up period. The remaining
55 patients (70%) had at least one sequentially increased PSA value
during their follow-up evaluation, typically of small magnitude
with subsequent resumption of a declining trend (median mag-
nitude 0.2 ng/mL; maximum 3.3 ng/mL; median time 24 months
out). Only 3/55 patients (5%) with a sequential PSA rise actually
went on to develop biochemical disease relapse.
Disease-free survival
With a minimum follow-up of 5-years, the biochemical-relapse
survival rates measure 100 and 92% for low-risk and intermediate-
risk cases, respectively, using the ASTRO biochemical-relapse-free
definition. Corresponding low-risk and intermediate-risk DFS
rates measure 98 and 92%, respectively, using the Phoenix def-
inition. Of added note, the only low-risk patient classified as
biochemically relapsed by Phoenix criteria, in fact, subsequently
proved to have a benign PSA bounce rather than a true relapse. Bio-
chemical DFS outcomes by risk group are illustrated in Figures 4
and 5. Clinically, the local relapse-free rate measured 100% for
low-risk and intermediate-risk cases, while the distant metastasis-
free survival rates measured 100 and 95% for low-risk and
intermediate-risk cases, respectively. For the entire study popu-
lation, the overall survival rate was 98%, with two deaths from
intercurrent disease, and prostate cancer-specific survival of 100%.
Toxicity
Toxicity scoring was by CTCAE v 3.0 criteria. The primary toxi-
city of this regimen for both acute and chronic time frames has
occurred in the GU Domain, with 10 and 9% acute and chronic
grade 2 toxicity rates, and 0 and 6% acute and chronic grade 3
GU toxicity rates, respectively. There were no instances of acute
catheter-dependent urinary retention in this series. Acute and
chronic toxicity in the GI domain has been far lower, with respec-
tive values of 0 and 1% for acute and chronic grade 2 or higher
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FIGURE 4 | Biochemical-relapse-free survival post-SBRT stratified by
risk-group: Phoenix definition.
FIGURE 5 | Biochemical-relapse-free survival post-SBRT stratified by
risk-group: ASTRO definition.
GI toxicity, respectively. There were no acute or chronic grade 3 or
higher GI toxicity events. The actuarial rate of Grade 2 or higher
GU and GI toxicity to 5 years is summarized in Figure 6.
We also evaluated potency at baseline and at annual inter-
vals post-treatment (Figure 7). Of the entire study population,
only 59% were sexually potent pre-treatment (defined as having a
SHIM score of ≥15). Limiting the analysis to those patients who
were potent pre-treatment, 65% remained potent 5 years out. Of
note, virtually the entire loss appears to have occurred during year
one post-SBRT, with a relatively stable rate of potency preservation
thereafter to 5 years.
DISCUSSION
Our initial hypothesis that the CyberKnife may be used to deliver
HDR-like dosimetry to the prostate non-invasively was originally
demonstrated by respective dosimetry comparisons as reported in
2008 (17). Now, 6 years later, we report 5-year biochemical and
clinical outcome results that also resemble those of HDR and
permanent source brachytherapy in a number of ways as detailed
below.
FIGURE 6 | Cumulative incidence of long-term grade 2 or higher GU or
GI morbidity, annualized to 5 years. There were no further events beyond
5 years in this study.
FIGURE 7 | Percent of patients with preserved potency – analysis
limited to those who were potent pre-SBRT. Note that virtually the entire
loss incidence occurs within year one post-SBRT, with relatively stable rates
thereafter.
PSA KINETICS POST-TREATMENT
The PSA nadir seen after “HDR-like” SBRT is very low and con-
tinues to decrease even beyond 5 years. By standard lab reporting,
which typically defines the PSA level as non-detectable at a value
of <0.1 ng/mL, that particular PSA nadir threshold was reached
5 years out. By ultrasensitive PSA analysis, which increases the
PSA detection sensitivity to very low levels, a further decrease
to a median PSA nadir of 0.02 ng/mL is seen 6 years out, sug-
gesting eventual “total PSA ablation” in the majority of patients
by this specific SBRT treatment method and dose fractionation
schedule. Similarly, following HDR brachytherapy and perma-
nent source brachytherapy, PSA nadirs of ≤0.1 ng/mL have also
been reported (24). Finally, “non-HDR-like” SBRT may also cre-
ate near ablation PSA levels post-treatment, though this has not
been universally observed and some SBRT series have reported
modestly higher median PSA nadir values. (1, 6, 25). Potentially,
this reflects a PSA ablation dose response aspect to non-HDR-
like SBRT regimens, with a minimum threshold dose of 35 Gy in
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five fractions or higher (prescribed to a volume rather than the
ICRU reference point) to routinely achieve a PSA nadir value
of 0.1 ng/mL or less. Somewhat higher PSA nadir values have
been reported following conventional fractionation external beam
radiotherapy, with a mature IMRT median PSA nadir result of
0.6 ng/mL reported by a large, experienced IMRT center (24).
Thus, it appears likely that HDR-like SBRT, aggressively frac-
tionated non-HDR-like SBRT and brachytherapy are relatively
radiobiologically more potent, typically ablating both prostate
cancer and normal prostate tissue. The slightly higher PSA nadir
seen post-conventional fractionation radiotherapy suggests that at
least some cells survive in the high-dose region long-term, though
this still does not establish de facto prostate cancer disease control
superiority to the PSA-ablative methods, as the trace higher PSA
levels seen post-conventional radiotherapy could be reflective of
small amounts of surviving normal prostate glands as opposed to
surviving cancerous glands. Of concern, however, is the clear cor-
relation of subsequent relapse with higher post-radiotherapeutic
PSA nadir levels, suggesting the possibility that total glandular
ablation may indeed be required to maximize the log-term DFS
probability (26–28). There was a large non-randomized series with
mature follow-up that did indeed observe a significantly lower PSA
nadir with brachytherapy versus IMRT, subsequently correlating
this “ablation level” post-brachytherapy PSA nadir with eventual
biochemical-relapse-free survival superiority, though no differ-
ence in the clinical DFS rate was observed (24). A higher rate
of grade 2 GU and GI toxicity was also seen in the brachyther-
apy patients in this series, suggesting a greater biologic potency
to adjacent normal tissues as well. Only well-controlled random-
ized clinical trials with very long follow-up would be able to assess
DFS or toxicity differences definitively, unfortunately, and none
are forthcoming soon.
DISEASE-FREE SURVIVAL
Our observed 100 and 92% 5-year biochemical-relapse-free sur-
vival rates for low-risk and intermediate-risk cases, respectively,
with a 100% 5-year local relapse-free survival rate, appears to
further corroborate the effectiveness and radiobiologic potency
of this HDR-like SBRT treatment method and dose fraction-
ation schedule. The few observed biochemical relapses in the
intermediate-risk group with subsequent clinical relapse have been
due to metastatic disease and these relapses have typically been
seen within the first 3 years post-treatment. This suggests that
occult disease beyond the prostate bed was present in these cases
even before their diagnosis and treatment. Although 10-year data
with a larger patient population are desirable to establish long-
term efficacy, the fact that an “ablation” median PSA nadir level
was obtained at a minimum post-SBRT follow-up interval of 5-
years suggests that the DFS result will be durable and competitive
with any other local prostate cancer treatment method described
to date.
COMPLICATIONS
Clearly, any radiotherapy regimen potent enough to produce a
PSA nadir level approaching zero has toxicity potential, and we
have indeed seen instances of grade 2 or higher toxicity in this
series. The primary toxicity occurred in the GU domain. Acutely
(<90 days), there was a 10% incidence of grade 2 GU toxicity and
a 0% incidence of grade 2 GI toxicity. Acute GU toxicity typically
peaked within the first month post-treatment, with an approxi-
mate 10 point median increase in the I-PSS score over baseline
at 2 weeks out, with steady improvement thereafter. Although this
specific SBRT regimen has substantially identical radiobiologic
potency versus HDR brachytherapy, upon which our dose frac-
tionation regimen was designed (3,800 cGy in four fractions),
there have been no observed cases of acute urinary retention.
Post-brachytherapy acute urinary retention has been reported fol-
lowing both permanent source and HDR prostate brachytherapy,
with an incidence of 3–12% with evidence of a reduced inci-
dence with technical refinements and increased experience of the
implanting team in one of these reports (10, 29–31). Presumably,
the major contributor to acute post-brachytherapy urinary reten-
tion is needle trauma. An obvious advantage of the current SBRT
approach is the absence of invasive transperineal needle punctures
or transcatheter delivery, and this advantage is clinically reflected
by the total lack of acute post-SBRT catheter-dependent urinary
retention. The insertion of a urethral catheter as practiced for
“HDR-like” SBRT treatment planning to define the position of the
urethra could also potentially contribute to very short-term GU
toxicity (rare cases of grade 1 only in this series – no obstruction).
Late toxicity is more likely a pure radiotherapy issue, with all of our
grade 3 GU toxicity cases occurring beyond a year – long after full
resolution of any short-term catheter-related GU toxicity issue.
Chronically (>90 days), we observed 9 and 6% rates of grade
2 and 3 GU toxicity, respectively. As the predicate series upon,
which we based our Virtual HDR SBRT regimen was the HDR
brachytherapy regimen described by the William Beaumont group
in 2004, it is not surprising that the incidence of grade 3 GU toxic-
ity in that series was comparable to our own observation (8% with
HDR brachytherapy in that series vs. 6% with “HDR-like” SBRT
in the current series) (12). Our prescribed dose is identical to their
HDR dose prescription, and delivered to a substantially equiva-
lent target volume. Although brachytherapy-associated catheter
trauma may contribute to short-term toxicity (<90 days), we pre-
sume that remaining or worsening late toxicity is more clearly
a reflection of the radiation effect itself; nearly identical chronic
grade 3 toxicity profiles between our series and its predicate HDR
brachytherapy series would appear to validate this presumption
(12). Regardless of the methodology used to deliver this dose
fractionation schedule, the best way to reduce the incidence of
serious chronic urinary tract toxicity probably lies in the patient
selection process. Relative caution in treating patients with preex-
isting urologic issues such as serious, chronic obstructive uropathy
would most likely reduce the incidence of serious chronic GU toxi-
city, regardless of the specific delivery methodology. If “HDR-like”
SBRT is practiced in the absence of accurate urethra localization,
the incidence of late grade 3 GU toxicity could potentially be fur-
ther increased, due to variable urethral location from patient to
patient that could create intended superimposition of extreme
intraprostatic radiotherapy dose escalation over some or all of an
incorrectly “estimated” urethra location. Finally, urologic instru-
mentation post-SBRT may also contribute to serious late GU
toxicity. At least one of our cases of late grade 3 GU toxicity were
immediately preceded by a cystoscopy procedure and a similar
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instrumentation versus grade 3 GU complication correlation was
previously reported by King et al. (32).
POTENCY PRESERVATION
Only 59% of our patients were sexually potent pre-SBRT, and
even that may be an optimistic assessment, as we defined “sexu-
ally potent” in this series as having a SHIM score of ≥15, whereas
“perfect” sexual function is defined by a SHIM score of 25. Some
degree of preexisting sexual dysfunction will inevitably be present
in any prostate cancer series and ours is no different, as their
median age was 68 years. Of patients who met our definition
of sexually potency prior to SBRT, 65% retained sexual potency
5 years post-treatment, with virtually the entire potency loss inci-
dence seen within the first year post-SBRT and relatively stable
potency preservation rates seen thereafter. Undoubtedly, in addi-
tion to the effect of radiotherapy itself on the NVB and/or penile
bulb, other factors may strongly influence the long-term potency
outcome, including patient age, presence versus absence of pre-
existing mild ED, vascular insults such as diabetes, hypertension,
and tobacco-induced small vessel disease. This series is too small to
effectively evaluate subgroups, though we expect our larger com-
panion,multi-institutional“Emulating HDR”prostate SBRT series
to shed further light on this issue (33). In fact, there has been a
preliminary potency outcome correlation reported in that series,
with advancing age and preexisting decreased SHIM score both
strongly predictive of an increased rate of subsequent post-SBRT
potency loss (33).
SUMMARY
We initially demonstrated that CyberKnife robotic SBRT rep-
resented a non-invasive method to deliver radiation dose dis-
tributions that very closely resembled those delivered by HDR
brachytherapy (17). We now have 5-year clinical outcomes that
demonstrate a similar DFS rate and PSA nadir versus that seen
with HDR prostate brachytherapy, minus the short-term hospi-
talization, catheter trauma, and acute urinary retention potential.
Grade 2 or higher long-term GU toxicity is seen with a similar
incidence between HDR-like SBRT versus actual HDR brachyther-
apy, with stricter patient selection or reduced SBRT dose inten-
sity representing potential strategies to reduce this. HDR-like
SBRT appears to represent a biologically potent local prostate
cancer treatment method, seemingly effectively combining “exter-
nal beam-like” non-invasiveness with “brachytherapy-like” conve-
nience and biologic potency. As such, this method appears to be a
potentially valuable addition to the prostate cancer local treatment
armamentarium.
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